NCT01461772

Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer

Comparison of Concurrent Chemoradiation Therapy With Weekly Cisplatin and Concurrent Chemoradiation Therapy With Weekly Carboplatin in Locally Advanced Cervical Cancer: Phase III Multicenter Prospective Randomized Controlled Trial

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: Female
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Concurrent chemoradiation therapy with weekly cisplatin is the current standard treatment for patients with locally advanced cervical cancer. However, weekly cisplatin is related to renal toxicity and not convenient regimen. Recently, carboplatin has proved to be a good radiosensitizer and less renal toxicity. Weekly carboplatin is more convenient regimen for both patients and physicians. Weekly carboplatin may have similar efficacy with weekly cisplatin and may have more favorable toxicity profile. Therefore, the investigators aimed to evaluate the efficacy and safety of concurrent chemoradiation with weekly carboplatin in patients with locally advanced cervical cancer.

Conditions

• Cervical Cancer

Interventions

Type	Name	Description
RADIATION	Radiation therapy	pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
DRUG	Carboplatin	carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
DRUG	Cisplatin	Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36

Timeline

• Start date: 2009-12-01
• Primary completion: 2014-05-01
• Completion: 2014-05-01
• First posted: 2011-10-28
• Last updated: 2017-05-31

Locations

1 site across 1 country: South Korea